NCT06627179 - Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 11, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Retinitis Pigmentosa (RP)Usher Syndrome Type 2Deaf BlindRetinal DiseaseEye Diseases, HereditaryEye Disorders CongenitalVision Disorders

Interventions

DRUG

Intravitreal Injection of Ultevursen

Up to 4 doses over a 24-month period

OTHER

No intervention, will not receive any active study intervention

Sham-procedure (no experimental drug administered)

Trial Locations (14)

19104

RECRUITING

University of Pennsylvania, Scheie Eye Institute, Philadelphia

48105

RECRUITING

University of Michigan- Kellogg Eye Center, Ann Arbor

53705

RECRUITING

University of Wisconsin- Madison, Madison

72076

RECRUITING

Universitätsklinikum Tübingen, Tübingen

75231

RECRUITING

Retina Foundation of the Southwest, Dallas

77030

RECRUITING

Baylor College of Medicine, Houston

94143

RECRUITING

The University of California, San Francisco, San Francisco

97239

RECRUITING

Casey Eye Institute, Oregon Health & Science University, Portland

02114

RECRUITING

Massachusetts Eye and Ear, Boston

M5G1E8

RECRUITING

Hospital for Sick Children, Toronto

H4A3J1

RECRUITING

McGill University Health Centre for Innovative Medicine, Montreal

OX3 9DU

RECRUITING

Oxford Eye Hospital, Headington

EH39HA

RECRUITING

University of Edinburgh / NHS Lothian, Edinburgh

EC1V 2PD

RECRUITING

Moorfields Eye Hosptial, London